论文部分内容阅读
目的比较10d序贯疗法与标准14d三联疗法治疗HP阳性消化性溃疡的近期疗效、副作用及远期疗效。方法 70例符合条件的患者随机分为两组,其中治疗组35例,前5d给予兰索拉唑、阿莫西林治疗,后5d给予兰索拉唑、替硝唑、克拉霉素治疗,之后给予兰索拉唑4周疗法;对照组35例给予兰索拉唑、阿莫西林、克拉霉素治疗14d,之后给予兰索拉唑4周治疗。治疗前、治疗4周后均进行胃镜和HP检查,评价近期疗效及不良反应情况;两组治疗结束后半年对治愈者HP复检,评价远期疗效。结果治疗组与对照组溃疡愈合率分别为91.42%和88.57%,两组间差异无统计学意义(P>0.05);HP根除率治疗组94.28%与对照组91.42%比较,两组间差异亦无统计学意义(P>0.05);两组不良反应发生率分别为14.28%、31.42%,两组比较有统计学意义(P<0.05);半年后对于治愈者复检HP,治疗组复发率6.25%和对照组22.58%,比较差异有统计学意义(P<0.05);治疗组费用-效益比好于对照组。结论 10d序贯疗法可作为治疗HP阳性消化性溃疡的首选疗法,副作用发生率低,费用效益比较低,复发率低。
Objective To compare the short-term curative effect, side effects and long-term curative effect of 10d sequential therapy and standard 14d triple therapy on HP-positive peptic ulcer. Methods A total of 70 eligible patients were randomly divided into two groups: 35 in the treatment group, lansoprazole and amoxicillin in the first 5 days and lansoprazole, tinidazole and clarithromycin in the 5th day after treatment Lansoprazole was given for 4 weeks. In the control group, 35 cases were treated with lansoprazole, amoxicillin and clarithromycin for 14 days, then lansoprazole for 4 weeks. Before treatment and after 4 weeks of treatment, gastroscopy and HP examination were performed to evaluate the short-term efficacy and adverse reactions. The two groups were re-tested for HP six months after the end of treatment to evaluate the long-term efficacy. Results The healing rates of ulcer in treatment group and control group were 91.42% and 88.57% respectively, there was no significant difference between two groups (P> 0.05). The difference between the two groups was 94.28% in HP eradication group and 91.42% in control group The incidence of adverse reactions in the two groups was 14.28% and 31.42%, respectively (P <0.05). After half a year, the relapse rate of the cured patients was higher than that of the cured ones 6.25% and control group 22.58%, the difference was statistically significant (P <0.05); the treatment group cost-benefit ratio better than the control group. Conclusion 10d sequential therapy can be used as the first choice for the treatment of HP-positive peptic ulcer. The incidence of side effects is low, the cost benefit is low and the recurrence rate is low.